Generex Establishes Branch Office in Dubai Healthcare City
Generex Biotechnology Corporation announced that it has received a Commercial License from the Government of Dubai, United Arab Emirates. Under the auspices of this Commercial License, Generex has established a branch office in exclusive Dubai Healthcare City operating as "Generex Biotechnology Corporation Mena" (i.e., Middle East and North Africa). Generex, through this branch office, will work closely with the regulatory and marketing personnel of Leosons General Trading Company, the Company's licensee in the region for the registration, importation, marketing, distribution, and sale of Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product.
"This augmented presence in the region will assist Generex to bring Generex Oral-lyn and its new paradigm for the treatment of diabetes to the more than 15 million patients with diabetes in the region," said William Abajian, Senior Executive Advisor, Global Strategic Alliances & Business Development for the Company. "We believe that Generex Oral-lyn(TM), as a safe, simple, fast, and effective alternative to prandial injections of insulin, is poised to become a standard element of the treatment paradigm for the estimated 1.5 million Type-1 patients with diabetes in the region as well as the estimated 2.7 million Type-2 patients with diabetes in the region for whom insulin is a part of the treatment regime," added Mr. Abajian.
Other news from the department business & finance
